R&D | Cutting-edge science and innovative research

News

Astellas pays $285m for Audax cancer drug, and other deals

Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.

News

Lilly's triple G overpowers Ozempic in diabetes trial

Eli Lilly has added another arrow to the quiver of new diabetes and obesity drug retatrutide, outperforming Novo's Ozempic in a head-to-head trial.

News

Ferring builds in reproductive health via $1.38bn Gameto buy

Switzerland's Ferring Pharma has reached an agreement to buy US fertility start-up Gameto for up to $1.38bn.

News

Anthropic sets out its biopharma ambitions in IPO doc

Anthropic says it is working with nine of the top 10 pharma groups in its IPO prospectus, which also reiterates AI's "existential risks to humanity."

News

ESMO26: Ris-rez offers hope of osteosarcoma breakthrough

There have been few improvements in the treatment of osteosarcoma for decades, but a new study suggests GSK's ris-rez could change that.

News

UK could get COVID vaccines early in 2021, ahead of other Eu...

COVID-19 vaccines could be approved and available early next year in the UK ahead of other European countries, after its national regulator began its own rolling reviews of shots from Astra

News

ANGLE raises £20m, eyes opportunity in immunotherapy trials

Liquid biopsy company ANGLE has raised £20m through a conditional placing on the London Stock Exchange which will be used to expand commercial opportunities.

Views & Analysis

NICE talking to you: Trends in early HTA engagement

With exclusive data from Freedom of Information (FOI) requests sent to the National Institute for Health and are Excellence (NICE), Leela Barham takes a look at the trend in early engagemen

Debates & Insights

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Webinars

Sponsored

Synthetic control arms in clinical trials: Making it happen

Across the industry, pharma companies are turning to AI and real-world data to address many of the challenges of running clinical trials.

R&D

Sponsored

How synthetic control arms are changing clinical trials

Clinical trials are involved, expensive, and have been done largely the same way for decades but with today’s technology all that can change. With drawn-out timelines and billions

News

Astellas pays $285m for Audax cancer drug, and other deals

Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.

News

GSK shares come under pressure from weaker vaccine sales

Shares in GSK fell on a decline in vaccine sales in Q3, although demand for other drugs was strong with signs that its revamp is starting to deliver.

Press Releases

Media Partner

PHARMAP 2027 Addresses the Future of Pharmaceutical Manufact...

Senior pharma professionals gather in Berlin on 19-20 April for the Pharmaceutical Manufacturing and Packaging Congress (PHARMAP) 2027

Press Releases

Partner Content

The Evolution Summit Announces September 2026 Program for Cl...

Marcus Evans announces The Evolution Summit, taking place September 28-29, 2026 at Park Hyatt Aviara Resort, Golf Club & Spa, San Diego, CA.

Views & Analysis

R&D

Auto vacuum sealed vaccines in manufacturing plant

Reliability in life sciences logistics: What good looks like

What constitutes a reliable supply chain is changing rapidly.

R&D

Cardiovascular disease today: NMR-based lipoprotein profilin...

pharmaphorum spoke with Andreas Wolf, chief technology officer at numares Health about NMR-based lipoprotein profiling and cardiovascular disease.

R&D

Wooden pawns on top of wooden block named BOARD

Changing Faces: Board of Director and Advisory Board hires, ...

September’s boardroom moves brought seasoned pharma executives, investors, and scientific leaders into new governance and advisory roles across the life sciences sector.

Deep Dive

R&D

Cancer misinformation is a trust problem, not just an inform...

R&D

The GLP-1 Reckoning

R&D

Designing obesity trials around real lives: How patient cent...

R&D

From obesity to outcomes abstract visual

Sponsored

The future of cardiometabolic trials: From obesity to outcom...

Gain practical insight into how leading experts are designing the next generation of cardiometabolic trials in an upcoming webinar from hVIVO

R&D

Sponsored

Exploring the future: Opportunities and challenges in cell a...

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies.

R&D

Sponsored

Beyond clinical: Boosting recruitment and retention with SDO...

The success of clinical trials hinges on a complex array of factors, many of which extend beyond traditional clinical care.

Podcasts

R&D

pharmaphorum podcast Episode 278, Shai Melcer, IIA

Bioconvergence & future human health, with Shai Melcer

Shai Melcer discusses bioconvergence, a multidisciplinary research and development approach that merges technologies.

R&D

pharmaphorum podcast Episode 272, Dr Harpreet Singh, Precision for Medicine

Understanding Operation Trialblazer, with Dr Harpreet Singh

Dr Harpreet Singh, CMO at Precision for Medicine, brings both an insider and outsider perspective to discussing Operation TRIALBLAZER.

R&D

Prevent-Stop-Cure: Diagnostics & chronic liver disease, with...

Video

R&D

Boosting biotech in Basel – with Valentina Francia

pharmaphorum speaks with Valentina Francia from Basel Area Business and Innovation about why many life sciences startups are finding success in Basel.

R&D

Sponsored

Beyond recruitment: Creating patient engagement that lasts

In the final episode of our patient- and site-centric solutions interview series, Zoltan Varga discusses the importance of PRE.

R&D

LSX 2026 with Sam Possemiers, MRM Health

Taking the microbiome seriously, with Sam Possemiers

pharmaphorum catches up with MRM Health founder and CEO Sam Possemiers at LSX 2026.

White Papers

R&D

Sponsored

From Alzheimer’s disease research to the real-world setting:...

In a new white paper, Lucid Strategy Consulting suggests three key themes for pharma strategists seeking market leadership in the Alzheimer's space.

R&D

Sponsored

A data-driven guide to small molecule drug discovery and dev...

A new white paper from Excelra takes a closer look at how discovery teams actually experience the small molecule development journey.

R&D

A man stood on a rock looking towards the horizon

Sponsored

A New Framework to Engineer Breakthrough Value for Medicines

A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.